Immunome (IMNM) Non-Current Debt (2020 - 2021)

Immunome's (IMNM) quarterly Non-Current Debt came in at $134000.0 in Q1 2021, little changed on a QoQ basis from $134000.0 in Q4 2020.

Analysis

Immunome (IMNM) Non-Current Debt (2020 - 2021) Analysis & Trends

Immunome (IMNM) has 2 years of Non-Current Debt data on file, last reported at $134000.0 in Q1 2021.

Quarterly Non-Current Debt changed N/A year-over-year to $134000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $134000.0 (changed N/A YoY) and the FY2020 annual result came in at $134000.0, changed N/A from the prior year.
Non-Current Debt steadied at $134000.0 in Q1 2021, from $134000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $195000.0 in Q3 2020 to a low of $134000.0 in Q4 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	591.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	882.16 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	8.96 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	546.77 Mn
10	Immunome	3.03 Bn	2.51 Bn	-	-

Historic Data

Download Data